Q1 2027 Sakar Healthcare Ltd Earnings Call Transcript
Key Points
- Strong financial performance in Q1 FY27 with revenue growth of 38% YoY to INR7,297 lakhs and EBITDA up 67% to INR2,125 lakhs, with margins improving to 29%.
- Oncology business is gaining momentum, with over 65 product contracts executed and 50+ advanced discussions, indicating growing global demand and acceptance.
- Regulatory pipeline is robust with 261 dossiers shared globally, 178 submitted, and 16 marketing authorizations received, providing increasing market access visibility.
- Backward integration is progressing with 21 oncology APIs developed in-house, including 16 with CEP approvals or applications, enhancing supply chain control and competitiveness.
- The Bavla Oncology Facility can support revenues of INR800-1,000 crores at optimal utilization over the next 4-5 years without major incremental capex, offering significant growth headroom.
- Technology transfer projects with leading pharma companies (Accord-Intas, Torrent, Emcure, Glenmark, Zydus) are creating long-term strategic partnerships, with 7 site variation approvals already secured.
- Export contribution remains low at INR6.5 crores in Q1 FY27, with the business still heavily reliant on domestic CMO and API sales.
- Marketing authorization approvals are slow, with only 16 received so far, and the company has limited control over the approval timeline.
- Commercialization of own MAs is in early stages, with only one MA held in Europe and initial dispatches facing teething problems like serialization and batch testing coordination.
- Non-oncology business growth is expected to be modest at 7-8% CAGR, with margins around 25%, limiting overall profitability improvement.
- The company is not currently leveraging government R&D grants, relying on self-funding for development, which may limit speed of innovation.
- Revenue run rate has been stagnant at INR70-75 crores for the last three quarters, with significant growth dependent on future export ramp-up that is yet to materialize.
Ladies and Gentlemen, Good day and welcome to Sagar Healthcare Limited Q1 FY27 Earnings Conference Call hosted by MUFGN.
(Operator Instructions).
I now hand the conference. Over to Ms. Sejal from MUFG Intime.
Thank you, and over to you, ma'am.
Thank you, Shruti.
Welcome to Sakar Healthcare Q1 FY27 Earnings Conference.
Today on the call, we have Mr. Bikandit Ghosh, Vice President, Strategy and Business Development, Mr. Dharmesh Thakkar, CFO, Mr. Bharat Soni, Company Secretary, and Ms. Pushpa Komani, Manager.
Before we proceed with the call, I would like to give a small disclaimer that the call may contain certain forward-looking statements which are based on the business opinions and expectations of the company as on date. A detailed disclaimer has been given in the company's investor presentation which is uploaded on the stock exchange.
Now, I would like to hand over the call to Ms. Pushpa. Over to you ma'am.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
